In conclusion, in advanced-stage ovarian cancer patients treated with NAC followed by IDS, CRS 3 was not associated with increased survival for BRCA1/2 mutation carriers than for patients without these mutations. The gene discussed is BRCA1; the disease is ovarian carcinoma.